Skip to content

Evaluation of an Ultra-speed Picosecond Laser for Treating Tattoos

Evaluation of an Ultra-speed Picosecond Laser for Treating Tattoos

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03386760
Acronym
PicoS
Enrollment
18
Registered
2017-12-29
Start date
2018-01-15
Completion date
2022-07-08
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tattoo; Pigmentation

Keywords

tattoo

Brief summary

The investigators developed an ultra-speed picosecond laser (20ps) with a 20gHz repetition rate that provide very promising results in vitro and in ex vivo skin to remove skin tattoos. The aim of this study is to evaluate the efficacy and tolerance of a new ultra-speed picosecond laser and to compare it to a nanosecond laser for treating black tattoos. In a first phase of the study 10 patients with black tattoos will be treated with increasing fluencies of the picosecond laser to the optimal parameters in terms of efficacy and tolerance. In a second phase, 10 additional subjects with black tattoos will be treated after central randomization on half of the tattoo with the picosecond laser (with the parameters determined in the first phase) and the other half treated with a nanosecond laser.

Interventions

DEVICELaser Utilisation PicoSecond

Laser utilisation for tattoo depigmentation 1 session every month for a total of 3 sessions

DEVICELaser Utilisation Nano-second

Laser utilisation for tattoo depigmentation 1 session every month for a total of 3 sessions

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Black tattoos with surface between 10 and 100 cm² * Skin type I to VI

Exclusion criteria

* Childbearing age women * Active dermatosis located on the tattoo * Personal history of hypertrophic scars or keloids * Pigmentary or vascular lesions located on the tattoo * Subject taking oral steroid or retinoid or have any risk of delayed healing problems * Acquired or hereditary conditions that could leead to a delayed healing * Allergy to xylocaine, prilocaine or lidocaine

Design outcomes

Primary

MeasureTime frame
Percentage of decrease of tattoos 2 months after the third session as compared to baseline on standardized pictures2 month after the end of laser utilisation

Secondary

MeasureTime frameDescription
Evaluation of Pain with EVA test2 months after one session of laser utilisation
Evaluation of tolerance2 months after one session of laser utilisationcorrelation between EVA test and dermatological clinical signs
satisfaction evaluation of depigmanetation tattoo2 months after one session of laser utilisationsatisfaction tests
Skin biopsiesimmediately after treatment

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026